Recombinant technology has crucial impact in therapy development. In microbial environment, Pathogenic bacteria such as Staphylococcus aureus produces alpha hemolysin protein. This protein is used as anticancer protein. alpha hemolysin gene was isolated from pathogenic S. aureus that was isolated from blood samples of patients (chrildren). This recombinant hia gene was produced alpha hemolysin protein by using competent E. coli as a host. The recombinant - toxin protein was used as anticancer agent.In this study that high concentration of -toxin (500 mil/ ml) was effected on the cell viability of four cells line ( HepG-2, HCT-116, MCF-7, A-549). The cell viability of cell lines were represented 31.69% in HepG-2, 36.27% in HCT-116, 78.95% in MCF-7, 67.28% in A-549. From our results, Alpha hemolysin protein had high inhibitory activity against HepG-2 and HCT-116, and had weak inhibitory activity against MCF-7 and A-549. Inconclusion,The production of recombinant - toxin was very simple process, low cost, high efficiency, non-toxic, high yield and no side effect.
The disease burden of human immunodeficiency virus (HIV) is substantially more prevalent among residents of the sub-Saharan Africa and Asia. The availability and affordability of highly active antiretroviral therapy (HAART) have significantly reduced the mortality among HIV-1 infected population, increase their life expectancy and quality of life. However, the poor financial conditions and lack of costly infrastructure in the developing countries hinder regular monitoring of HIV-1 RNA (viral load) and CD4+ T-lymphocyte cell count (TCD4+ cell count). Under these circumstances, there is an increasing need for alternate biomarkers for monitoring the progression of the disease and patient management. Albumin, hemoglobin (Hb), dehydroepiandrosterone sulfate (DHEA-S), red blood cell (RBC) count, erythrocyte sedimentation rate (ESR), plasma highly-sensitive C-reactive protein (hs-CRP), hematocrit (Hct), total lymphocyte count (TLC) are some of the alternate biomarkers with proven utility in the assessment of disease progression.